Karyopharm Therapeutics, Inc. (KPTIQ)
0.025
-0.01
(-26.25%)
USD |
OTCM |
Nov 20, 16:00
Karyopharm Therapeutics Research and Development Expense (TTM) : 120.81M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 120.81M |
| March 31, 2026 | 124.57M |
| December 31, 2025 | 125.32M |
| September 30, 2025 | 130.89M |
| June 30, 2025 | 136.52M |
| March 31, 2025 | 142.09M |
| December 31, 2024 | 142.89M |
| September 30, 2024 | 148.98M |
| June 30, 2024 | 148.40M |
| March 31, 2024 | 141.51M |
| December 31, 2023 | 138.22M |
| September 30, 2023 | 129.74M |
| June 30, 2023 | 125.44M |
| March 31, 2023 | 138.20M |
| December 31, 2022 | 148.04M |
| September 30, 2022 | 161.09M |
| June 30, 2022 | 168.18M |
| March 31, 2022 | 157.77M |
| December 31, 2021 | 152.70M |
| September 30, 2021 | 145.76M |
| June 30, 2021 | 144.30M |
| March 31, 2021 | 152.90M |
| December 31, 2020 | 149.84M |
| September 30, 2020 | 144.25M |
| June 30, 2020 | 133.72M |
| Date | Value |
|---|---|
| March 31, 2020 | 117.88M |
| December 31, 2019 | 122.10M |
| September 30, 2019 | 129.65M |
| June 30, 2019 | 139.81M |
| March 31, 2019 | 158.02M |
| December 31, 2018 | 161.37M |
| September 30, 2018 | 157.32M |
| June 30, 2018 | 146.12M |
| March 31, 2018 | 124.51M |
| December 31, 2017 | 107.27M |
| September 30, 2017 | 93.11M |
| June 30, 2017 | 87.77M |
| March 31, 2017 | 89.23M |
| December 31, 2016 | 86.94M |
| September 30, 2016 | 90.33M |
| June 30, 2016 | 96.36M |
| March 31, 2016 | 98.79M |
| December 31, 2015 | 97.74M |
| September 30, 2015 | 93.72M |
| June 30, 2015 | 83.75M |
| March 31, 2015 | 69.90M |
| December 31, 2014 | 60.13M |
| September 30, 2014 | 49.78M |
| June 30, 2014 | 41.53M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Heron Therapeutics, Inc. | 11.93M |
| Tonix Pharmaceuticals Holding Corp. | 80.40M |
| Minerva Neurosciences, Inc. | 19.77M |
| Corbus Pharmaceuticals Holdings, Inc. | 103.65M |
| Ocugen, Inc. | 45.12M |